What I personally think will happen is that we'll never hit a steady state of nameplate capacity. Instead the company will lower the targeted tonnage and lower overheads proportionally. Maybe to, say, 800 instead of 1200.
I think we could then see this smaller plant produce more around the 2-4million PA profit rather than the estimated 8.
In my opinion this will still allow a 'proof of procedure' to the business model, thus giving high chance of funding.
The main thing is to be in the black with a sustainable rate of production, not to hit an unrealistic nameplate capacity on a plant that simply isnt designed for the process.
Otherwise, the procedure itself may just be a dud, but the fact they have had good amounts produced for 24 or 48 hours straight tends to suggest its not.
- Forums
- ASX - By Stock
- VYS
- "writings on the wall" or are there positives!
"writings on the wall" or are there positives!, page-9
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
Add VYS (ASX) to my watchlist
(20min delay)
|
|||||
Last
50.0¢ |
Change
0.035(7.53%) |
Mkt cap ! $258.7M |
Open | High | Low | Value | Volume |
47.0¢ | 51.0¢ | 46.5¢ | $702.9K | 1.449M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 49.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 13965 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 0.495 |
2 | 15000 | 0.490 |
7 | 117821 | 0.485 |
1 | 13965 | 0.480 |
5 | 57835 | 0.475 |
Price($) | Vol. | No. |
---|---|---|
0.500 | 13965 | 1 |
0.505 | 28965 | 3 |
0.510 | 27415 | 6 |
0.515 | 105000 | 2 |
0.525 | 70000 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
VYS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online